Loading
A phase 1/2 trial of NECVAX-NEO1 in advanced solid tumours, run by NEC Bio B.V, active and no longer recruiting.
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT06631079 by NEC Bio B.V, with 20 participants enrolled, started 2024-10-07 and due to reach its primary completion in 2026-07-31. Interventions recorded: NECVAX-NEO1.
Shares PD-L1, PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PD-1, Metastatic cancer (cancer that has spread) and the tag pipeline.